Cargando…
A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer
BACKGROUND: Gefitinib is an oral EGFR tyrosine kinase inhibitors which may act as a radiosensitizer. PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by...
Autores principales: | Levy, Antonin, Bardet, Etienne, Lacas, Benjamin, Pignon, Jean-Pierre, Adam, Julien, Lacroix, Ludovic, Artignan, Xavier, Verrelle, Pierre, Le Péoux, Cécile |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362534/ https://www.ncbi.nlm.nih.gov/pubmed/27764781 http://dx.doi.org/10.18632/oncotarget.12741 |
Ejemplares similares
-
Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients
por: Boros, Angela, et al.
Publicado: (2017) -
Impact of missing individual patient data on 18 meta-analyses of randomised trials in oncology: Gustave Roussy experience
por: Fayard, Florence, et al.
Publicado: (2018) -
High dose rate brachytherapy before external beam irradiation in inoperable oesophageal cancer.
por: Taal, B. G., et al.
Publicado: (1996) -
Long‐term outcome of concurrent chemoradiotherapy with elective nodal irradiation for inoperable esophageal cancer
por: Jing, Zhao, et al.
Publicado: (2017) -
Inoperable Cancer
Publicado: (1901)